Recent News

ASCO 2022: Combination Therapy With Umbilical Cord Blood–Derived Natural Killer Cells for Myeloma

ASCO 2022: Mobocertinib Versus Amivantamab-vmjw in Treatment of EGFR-Mutated NSCLC

Cemiplimab-rwlc in Squamous Cell Carcinoma of the Skin: Living in the Real World

Lisocabtagene Maraleucel Approved by FDA in Second-Line Treatment of LBCL

ASCO 2022: Eftilagimod Alpha Plus Pembrolizumab in NSCLC

ASCO 2022: Phase II MagnetisMM-3 Trial Focuses on Elranatamab in Resistant Myeloma

ASCO 2022: Amivantamab-vmjw Under Study in NSCLC With Primary MET Exon 14 Skipping Mutation

ASCO 2022: PD-1 Inhibitory–Refractory Merkel Cell Carcinoma: Is T-Cell Therapy a Step in the Right Direction?

ASCO 2022: Tislelizumab Plus Nab-Paclitaxel Under Study in Urothelial Bladder Cancer

ASCO 2022: Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Follicular Lymphoma

Baseline Body Mass Index and Outcomes in Chemoimmunotherapy-Treated Lung Cancer

After CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma: What’s Next?

ASCO 2022: Update From Cohort A of CARTITUDE-2 on Ciltacabtagene Autoleucel in Myeloma

ASCO 2022: Updated Safety Data From DESTINY-Breast03 on T-DXd Versus T-DM1 in Metastatic Breast Cancer

ASCO 2022: COSMIC-021 Cohorts of Cabozantinib Plus Atezolizumab in Urothelial Cancer

EHA 2022: Patient-Reported Outcomes With Lisocabtagene Maraleucel in LBCL

ASCO 2022: Ixazomib Plus Daratumumab in Elderly Frail Patients With Resistant Multiple Myeloma

ASCO 2022: 2-Year Follow-up on Enfortumab Vedotin for Urothelial Cancer

ASCO 2022: Adjuvant Cemiplimab-rwlc Under Study in High-Risk Cutaneous Squamous Cell Carcinoma

EHA 2022: Preliminary Data From PACIFIC Trial of Nivolumab Plus Brentuximab Vedotin in LBLC

ASCO 2022: Novel HER3-Directed Antibody-Drug Conjugate Under Study in Metastatic Breast Cancer

ASCO 2022: CHRYSALIS-2 Update on Amivantamab-vmjw Plus Lazertinib in NSCLC

EHA 2022: Fixed Duration of Bispecific Antibody Glofitamab in Resistant DLBCL

ASCO 2022: Early-Phase Study of Talquetamab in Resistant Multiple Myeloma

ASCO 2022: Pathologic Regression and Event-Free Survival With Nivolumab Plus Chemotherapy for NSCLC

ASCO 2022: Immunotherapy Followed by Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma

ASCO 2022: Extended Follow-up With Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASCO 2022: 3-Year Follow-Up From ZUMA-2 Trial of KTE-X19 in Resistant Mantle Cell Lymphoma

ASCO 2022: 3-Year Trial Update on Nivolumab Plus Ipilimumab and Chemotherapy for Metastatic NSCLC

ASCO 2022: Update From CARTITUDE-1 on Ciltacabtagene Autoleucel in Refractory Myeloma

ASCO 2022: Oncolytic Virus Plus Cemiplimab-rwlc Under Study in Cutaneous Squamous Cell Cancer

ASCO 2022: DESTINY-Breast04 Reports Benefit of T-DXd in HER2-Low Metastatic Breast Cancer

ASCO 2022: Second-Line Pembrolizumab Plus Ramucirumab in Advanced NSCLC

ASCO 2022: Neoadjuvant Targeting of PD-1 Plus SBRT in Muscle-Invasive Bladder Cancer

ASCO 2022: TROPiCS-02 Meets Study Endpoint With Sacituzumab Govitecan-hziy in Advanced Breast Cancer

ASCO 2022: Does Dosing Frequency and Duration of Anti–PD-1 Therapy Impact Outcomes in Skin Cancers?

ASCO 2022: Neoadjuvant Enfortumab Vedotin-ejfv in Cisplatin-Ineligible Bladder Cancer

ASCO 2022: Ibrutinib Plus Chemoimmunotherapy in Older Patients With Mantle Cell Lymphoma

Novel Triplet Under Study in Advanced Immunomodulatory Triple-Negative Breast Cancer

Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL

Predicting Remission With CAR T-Cell Therapy in Large B-Cell Lymphoma: Focus on FDG-PET Imaging

Can Immune Checkpoint Inhibitors Improve Pathologic Complete Response in Breast Cancer?

IMpower150 Mutational Subgroup Analysis of Chemoimmunotherapy for KRAS-Mutated Lung Cancer

Trial of Intravesicular Adenovirus Vector Therapy in Bladder Cancer Unresponsive to BCG

Vaccine Plus Co-stimulated T Cells Under Study in Multiple Myeloma

Can Addition of T-DM1 Improve Outcomes Over Standard Treatment in HER2-Positive Breast Cancer?